We'll discuss the telehealth regulatory and policy changes enacted during the COVID-19 pandemic, what may change in 2021, and what’s likely to remain the same regarding the reimbursement of remote care.
Find the CANCER BUZZ podcast on Apple Podcasts, Spotify, or wherever you get your podcasts!
Long lagging in acceptance from providers, patients, and payers, telehealth has undergone a renaissance in use due to the COVID-19 pandemic, enabling millions of people to receive care remotely for the first time. Patient advocates who had lobbied for the reimbursement of remote& care for years saw a drastic reversal of policies, with public and private payers suspending their rules which had previously limited reimbursement for telehealth.
Now that the pandemic appears to be ebbing in parts of the country, providers are wondering whether the regulatory and policy changes enacted during 2020 will remain. In this episode of CANCER BUZZ, we talk about what may change and what’s likely to remain the same regarding reimbursement for telehealth this year and beyond.
Guests: Mei Wa Kwong, JD, Executive Director, Center for Connected Health Policy
Related Content:
The views and opinions expressed herein are those of the author(s)/faculty member(s) and do not reflect the official policy or position of their employer(s) or the Association of Cancer Care Centers.
July 8, 2026
June 30, 2026
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
